Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Voyager Therapeutics and its officers or directors [1] Group 1: Company Developments - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS), citing emerging preclinical data indicating that the siRNA payload component of VY9323 does not meet their standards due to off-target effects [2] - Following this announcement, Voyager's stock price dropped by $1.11 per share, or 20.86%, closing at $4.21 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene thera ...

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025. A webcast of the presentation will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archive ...

About six months ago, I wrote an article on Voyager Therapeutics, Inc. (NASDAQ: VYGR ) highlighting the pipeline advances and stable financial position, supporting a “Strong Buy” rating. Given that VYGR’s shares have fallen by 35% sinceOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...

Investors might want to bet on Voyager Therapeutics (VYGR) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of ...

Shares of Voyager Therapeutics (VYGR) have gained 4.2% over the past four weeks to close the last trading session at $6.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.50 indicates a potential upside of 152.5%.The average comprises 10 short-term price targets ranging from a low of $11 to a high of $30, with a standard deviation of $5.36. While the lowest estimate indicat ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 64.44%. A quarter ago, it was expected that this gene therapy company would post a loss of $0.38 per share when it actually produced a loss of $0.18, delivering a surprise of 52.63%.Over the last four quarters, the co ...

- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer’s - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be a ...

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the ...